GlassScriptPhysician profile
Thomas R Scales
NPI 1437204732
$10,002.32
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $9,408.55 | 2019 | |
| Allergan, INC. | $184.46 | 2019 | |
| Gilead Sciences, INC. | $133.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $54.83 | 2019 | |
| Orexo US, INC. | $44.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $41.38 | 2019 | |
| Kaleo, INC. | $29.55 | 2019 | |
| Mdd US Operations, LLC | $27.34 | 2019 | |
| Lundbeck LLC | $18.89 | 2019 | |
| Vanda Pharmaceuticals INC. | $17.81 | 2019 | |
| Amgen INC. | $15.78 | 2019 | |
| Alkermes, INC. | $13.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.